Hereditary Amyloidosis

Hereditary Amyloidosis is a type of amyloidosis that runs in families. It happens when your body produces too much of a protein called amyloid. This protein builds up in organs like your heart, kidneys, and nerves, causing problems over time. It's a genetic condition, meaning it's passed down from parents to children.

Condition

What people with Hereditary Amyloidosis report

Every report comes from a Lived member, sent anonymously.

Have you tried Amvuttra (Vutrisiran) for Hereditary Amyloidosis?

NameHow it went

About Hereditary Amyloidosis

What It Is

Hereditary amyloidosis is an inherited condition in which a protein made by the body folds abnormally and builds up as deposits, called amyloid, in the nerves, the heart and other organs. Over time those deposits stiffen and damage the tissues they collect in, so the organs stop working as they should. Symptoms usually begin in adulthood, anywhere from the 20s to the 70s, depending on the gene variant and the family. Most cases involve a protein called transthyretin (TTR), which normally carries vitamin A and thyroid hormone in the blood. Doctors call this form hereditary transthyretin amyloidosis, often shortened to hATTR or ATTRv. It mainly affects two systems. When it affects the nerves, people notice numbness, tingling, pain or weakness in the hands and feet, along with problems in the nerves that run automatic body functions: diarrhea or constipation, bladder and sexual problems, and dizziness from a drop in blood pressure on standing. When it affects the heart, the heart wall thickens and stiffens, leading to breathlessness, swelling and irregular heart rhythms. Many people have some of both, and carpal tunnel syndrome (numbness and tingling in the hand and fingers) can be an early clue. The eyes and kidneys can also be involved. Hereditary amyloidosis is different from two types that are not inherited: wild-type transthyretin (ATTR) amyloidosis, in which normal transthyretin builds up in the heart with age, and light-chain (AL) amyloidosis, which comes from a blood cell disorder. The distinction matters because each is treated differently.

Causes & Risk Factors

Hereditary transthyretin amyloidosis is caused by a change (variant) in the TTR gene. Transthyretin normally travels through the blood as a group of four linked units. The variant makes that group less stable, so it breaks apart more easily, and the loose pieces stick together into fibers that collect as amyloid. Transthyretin is made mainly in the liver, which is why treatments target its production there. The condition is inherited in an autosomal dominant pattern, meaning one copy of the variant from one parent is enough to cause it. Each child of a person who carries a variant has a 50 percent chance of inheriting it. Carrying a variant does not guarantee illness, though: not everyone who carries one develops symptoms, and the age at onset and the organs affected can differ even within one family. More than 100 TTR variants are known, and each tends toward its own pattern. One variant, V142I (also written V122I), is found mainly in people of African ancestry, including many African Americans; it chiefly affects the heart, usually after age 50. Another, V30M, is common in parts of Portugal, Sweden and Japan and mainly affects the nerves. Outside the regions where a variant is common, many people are diagnosed with no known family history. Rarer hereditary amyloidoses involve other proteins, such as gelsolin, and behave differently.

How It's Diagnosed

Because the symptoms overlap with far more common problems, such as other causes of nerve damage, carpal tunnel syndrome or heart failure, diagnosis is often delayed. Clinicians become suspicious when nerve damage keeps progressing without a clear cause, especially alongside digestive or blood pressure problems, heart trouble or a family history, or when the heart wall is unexpectedly thick. Several tests can confirm it. A genetic blood test looks for a TTR variant, and it is what separates the hereditary form from wild-type ATTR. A tissue sample (biopsy) from an affected area can show amyloid directly and identify which protein it is made of. When the heart is involved, a nuclear heart scan using a technetium tracer (sometimes called a PYP or DPD scan) can show transthyretin amyloid without a heart biopsy. That scan is read together with blood and urine tests for abnormal antibody fragments, because light-chain amyloidosis has to be ruled out; it needs entirely different treatment. Once the diagnosis is made, tests such as an echocardiogram (heart ultrasound), cardiac MRI, heart blood markers, nerve conduction studies and eye exams show which organs are affected and give a baseline for tracking change.

Treatment Options

Treatment has changed a great deal in recent years. In the past, the main option was a liver transplant, which removes the main source of the abnormal protein. Today, medicines that act on transthyretin itself are the standard, and expert guidance is to start them as soon as possible after diagnosis, before more nerve or heart damage builds up. Gene-silencing medicines reduce how much transthyretin the liver makes, so less is available to form new deposits. Vutrisiran (Amvuttra) is an injection under the skin given by a health professional every three months, and it is approved both for the nerve form and for heart disease caused by transthyretin amyloid. Patisiran (Onpattro) is an intravenous infusion every three weeks, and eplontersen (Wainua) is a monthly injection under the skin; both are approved for the nerve form. Because transthyretin carries vitamin A, these medicines lower vitamin A levels, so people take a daily vitamin A supplement at the standard recommended amount, not higher doses. Stabilizers are pills that hold transthyretin in its normal four-part shape so it is less likely to break apart. Tafamidis (Vyndaqel or Vyndamax), taken once daily, and acoramidis (Attruby), taken twice daily, are approved in the US for heart disease caused by transthyretin amyloid, where they reduce deaths and hospital stays from heart causes. In the nerve form, trials of each medicine against placebo suggest the gene-silencing medicines improve nerve-related quality of life more than tafamidis, but no trial has compared them directly. The choice depends mainly on which organs are affected and how a person prefers to receive treatment. Alongside these medicines, care addresses each affected system, such as heart failure and rhythm treatment, relief for nerve pain, and help with digestive, bladder and blood pressure problems. Because the condition touches many organs, care is often coordinated by a specialist amyloidosis center.

What to Expect

Hereditary transthyretin amyloidosis is progressive. Before current treatments, it typically led to increasing disability and death within about 3 to 15 years of symptoms starting, depending on the variant and the organs involved. Current medicines aim to change that course, and how well they do so depends partly on how early they begin. Daily life also varies widely: some people mainly live with nerve symptoms that affect walking, hand use and digestion, while others mainly face heart failure that limits exertion. Living with the condition usually means regular follow-up with a team that may include a neurologist, a cardiologist and a genetic counselor, with repeated heart and nerve tests to check whether the disease is stable. Injections or infusions on a set schedule, daily pills, or both become part of routine life. A diagnosis also affects relatives. Adult brothers, sisters and children can be offered genetic counseling and, if they choose, a test to learn whether they carry the variant. Testing is not recommended for children without symptoms until they are adults and can decide for themselves. Carriers without symptoms are usually offered heart and nerve checks starting about 10 years before the age at which the condition typically begins for their variant, so that early signs are caught.

When to Seek Help

See a doctor about numbness, tingling or weakness that keeps getting worse, carpal tunnel syndrome without a clear reason, unexplained digestive or bladder changes, or dizziness on standing, especially if relatives have had similar problems or heart failure, and ask whether amyloidosis has been considered. If a relative has been diagnosed, ask about genetic counseling even if you feel well. If you have the condition, contact your care team promptly about new or worsening shortness of breath, swelling in the legs or ankles, fainting or near-fainting, or a racing or irregular heartbeat, since these can signal heart involvement or progression. While taking a gene-silencing medicine, report trouble seeing in the dark, which can reflect low vitamin A.

Questions to Ask Your Doctor

  1. 1.Which TTR variant do I have, and what does it usually mean for which organs are affected and when?
  2. 2.Which organs are involved now, and which tests will we repeat to track them?
  3. 3.What are the trade-offs between a gene-silencing medicine and a stabilizer in my situation?
  4. 4.Should my care be coordinated with a specialist amyloidosis center?
  5. 5.How should I approach my relatives about genetic counseling and testing?

Last reviewed • Oct 2026

Educational content, not medical advice.